A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2001
12/20/2001	CA2411811A1 Sulfonamide derivatives
12/20/2001	CA2411805A1 Serine protease inhibitors
12/20/2001	CA2411798A1 Serine protease inhibitors
12/20/2001	CA2411495A1 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase
12/20/2001	CA2411472A1 Cd154 variants
12/20/2001	CA2411116A1 Indole derivatives and their use as 15-lipoxygenase inhibitors
12/20/2001	CA2411036A1 Combinatorial production of nucleotide and nucleoside (xitp)analogues
12/20/2001	CA2410171A1 Novel heterocyclic analogs of diphenylethylene compounds and uses thereof
12/20/2001	CA2408575A1 Cosmetic and/or dermatological composition based on cocoa extracts
12/20/2001	CA2407699A1 Use of an aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects
12/20/2001	CA2382065A1 Bioavailable dosage form of isotretinoin
12/19/2001	EP1164196A1 Retroviral vectors
12/19/2001	EP1164145A2 Non-anticoagulant desulfated heparins as medicaments
12/19/2001	EP1164138A1 Terpyridine-platinum (II) complexes
12/19/2001	EP1164136A1 Long wavelength absorbing bacteriochlorin alkyl ether analogs
12/19/2001	EP1164135A1 Substituted metal-phthalocyanines, their preparation and the use thereof
12/19/2001	EP1164134A1 Benzimidazole compounds and their use as modulators of the GABA A receptor complex
12/19/2001	EP1164133A2 Enantiomerically pure Beta-D-(-)-dioxolane-nucleosides
12/19/2001	EP1164132A2 Crystalline magnesium omeprazole
12/19/2001	EP1163910A1 Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
12/19/2001	EP1163909A2 Use of sugar ethers as immunity adjuvant in vaccine compositions, therapeutic compositions containing them and their use as vaccine
12/19/2001	EP1163908A1 Water-soluble complex of an extract of Ginkgo Bilboa, process for the preparation thereof and composition comprising the same
12/19/2001	EP1163907A1 Use of l-threo-methylphenidate for the treatment of depression
12/19/2001	EP1163906A2 Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen
12/19/2001	EP1163905A1 Skin preparations for external use
12/19/2001	EP1163904A1 Composition for the prevention of smooth muscle diseases comprising ascorbate, arginine and magnesium
12/19/2001	EP1163903A2 Methanal injection treatment for animal epidemics
12/19/2001	EP1163902A2 Transdermal preparation containing hydrophilic or salt-form drug
12/19/2001	EP1163528A2 Prediction of diabetes impaired wound healing
12/19/2001	EP1163524A2 Methods of screening for colorectal cancer modulators
12/19/2001	EP1163523A1 Method for detecting predisposition to a venous thromboembolic disease
12/19/2001	EP1163522A1 Method for detecting superantigen activity in a biological sample
12/19/2001	EP1163373A1 Antisense modulation of cellular inhibitor of apoptosis-1 expression
12/19/2001	EP1163364A1 Screening method involving mgdg synthase
12/19/2001	EP1163342A1 Chlamydia antigens and corresponding dna fragments and uses thereof
12/19/2001	EP1163335A1 MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION
12/19/2001	EP1163333A2 Inhibitors of endothelin-1 synthesis
12/19/2001	EP1163331A1 50 human secreted proteins
12/19/2001	EP1163274A1 Process for cross-linking hyaluronic acid to polymers
12/19/2001	EP1163270A1 Dihydroouabain-like factor and diagnostic and therapeutic compositions and methods
12/19/2001	EP1163262A1 Phenylalanine derivatives
12/19/2001	EP1163259A1 14.beta.,17-alpha-hydroxymethylandrostane derivatives as androgens
12/19/2001	EP1163258A1 22r-hydroxycholesta-8,14-diene derivatives for the inhibition of meiosis
12/19/2001	EP1163256A1 Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
12/19/2001	EP1163255A1 50 human secreted proteins
12/19/2001	EP1163254A2 Trpm-2 antisense therapy
12/19/2001	EP1163247A1 Pharmaceutical compositions comprising metal complexes
12/19/2001	EP1163246A1 Organic-arsenic compounds
12/19/2001	EP1163244A1 Thienopyrimidine compounds, their production and use
12/19/2001	EP1163243A2 Calanolides for inhibiting btk
12/19/2001	EP1163242A2 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
12/19/2001	EP1163239A1 Modified amino-acid amides as cgrp antagonists
12/19/2001	EP1163238A1 Chemokine recpetor binding heterocyclic compounds
12/19/2001	EP1163237A1 Amide derivatives
12/19/2001	EP1163236A1 Aromatic heterocyclic compounds as anti-inflammatory agents
12/19/2001	EP1163234A1 Improved aqueous solubility pharmaceutical formulations
12/19/2001	EP1163233A1 Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
12/19/2001	EP1163228A1 Quinazolines and therapeutic use thereof
12/19/2001	EP1163227A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
12/19/2001	EP1163226A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
12/19/2001	EP1163225A1 Compounds and methods for modulation of estrogen receptors
12/19/2001	EP1163224A1 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
12/19/2001	EP1163221A1 Sulfonamide derivatives as 5ht7 receptor antagonists
12/19/2001	EP1163220A1 Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist
12/19/2001	EP1163219A1 Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
12/19/2001	EP1163218A1 New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
12/19/2001	EP1163217A1 New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
12/19/2001	EP1163213A1 Hydroxamic and carboxylic acid derivatives
12/19/2001	EP1163212A1 Amide derivatives
12/19/2001	EP1163208A2 Caspase inhibitors and uses thereof
12/19/2001	EP1163204A1 Lipoxin compounds and their use
12/19/2001	EP1163203A1 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
12/19/2001	EP1163200A1 Method of industrial-scale purification of lactic acid
12/19/2001	EP1163195A1 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction
12/19/2001	EP1163029A2 Nitrate esters and their use for inducing neuroprotection and cognition enhancement
12/19/2001	EP1163017A1 Muscle tissue engineering
12/19/2001	EP1163011A2 Fatty acid-anticancer conjugates and uses thereof
12/19/2001	EP1163009A1 Gel-microemulsion formulations
12/19/2001	EP1163007A1 Propofol formulation containing tris
12/19/2001	EP1163006A1 Method to prevent xenograft transplant rejection
12/19/2001	EP1163005A1 Model and method for angiogenesis inhibition
12/19/2001	EP1162984A2 Use of cross linked polysaccharides for the inhibition of angiogenesis
12/19/2001	EP1162982A2 Use of stabilised oligonucleotides for preparing a medicine with antitumour activity
12/19/2001	EP1162981A1 Treatment of accidental extravasation of anthracyclines
12/19/2001	EP1162980A2 Use of pyridoxine compounds for the treatment of cardiovascular and related pathologies
12/19/2001	EP1162979A2 Cyclic glycerophosphates and analogs thereof
12/19/2001	EP1162978A1 Method for treating and/or preventing retinal diseases with sustained release corticosteroids
12/19/2001	EP1162977A1 (androst-5-en-17beta-yl)alkyl sulfoxides and sulfones and their use for the control of fertility
12/19/2001	EP1162976A2 Regulation of phospholipase d activity
12/19/2001	EP1162974A1 Quinazoline formulations and therapeutic use thereof
12/19/2001	EP1162973A1 Cilostazol preparation
12/19/2001	EP1162972A2 Devices and methods for pain management
12/19/2001	EP1162971A2 Use of a non-nucleoside reverse transcriptase inhibitor (nni) for the treatment of hiv infection
12/19/2001	EP1162970A2 Anti-inflammatory uses of manzamines
12/19/2001	EP1162969A2 Compositions for improving fertility
12/19/2001	EP1162968A1 Use of epigallocatechin-gallate for inhibiting angiogenesis
12/19/2001	EP1162967A1 The use of certain affinity nmda antagonists as antidepressants
12/19/2001	EP1162966A1 Weight loss after pregnancy
12/19/2001	EP1162965A1 Method of controlling weight gain associated with therapeutic drugs
12/19/2001	EP1162964A1 Treatment of pulmonary hypertension

1 ... 5941 5942 5943 5944 5945 5946 5947 5948 5949 5950 5951 5952 5953 5954 5955 5956 5957 5958 5959 5960 5961 ... 7860